In 2024, Novo Nordisk Latvia SIA had revenue of 19.8 million EUR and profit of 773.7 thousand EUR. The company has 21 employees. Beneficial owners: Anders Kaae, Barbara Casadei, Christopher Ashby Voigt and 9 more.
| year | 2024Latest | 2023 |
|---|---|---|
Revenue | 19,8m € +508.5% | 3,3m € |
Profit | 773,7k € +529.0% | 123k € |
Assets | 6,4m € +299.3% | 1,6m € |
Liabilities | 5,2m € +341.1% | 1,2m € |
Equity | 1,1m € +239.5% | 323k € |
Employees | 21 +5.0% | 20 |
Overall rating | A+99/100 |
Financial health | 100/100 |
Credit history | 100/100 |
Legal history | 100/100 |
Business activity | 95/100 |
| Overall risk | Low |
No risk flags | |
No tax debts | |
Positive profit | |
Regular report filing | |
| Name, surname | Birth date | Position | Representation rights | Registered | |
|---|---|---|---|---|---|
| - | Board member | Together with at least | |||
| - | Board member | Together with at least | |||
| - | Board member | Together with at least |
Novo Nordisk Latvia SIA is located at Mārupes nov., Mārupe, Kārļa Ulmaņa gatve 119, LV-2167.
In 2024, Novo Nordisk Latvia SIA had revenue of 19 816 379 EUR and profit of 773 715 EUR. Compared to previous year, revenue increased by 508.5%. View full financial report →
In 2024, Novo Nordisk Latvia SIA had an average of 21 employees. View tax history →
The beneficial owners of Novo Nordisk Latvia SIA are Anders Kaae, Barbara Casadei, Christopher Ashby Voigt, Lars Green, Lars Henrik Munch, Lars Rebien Sorensen, Lena Bech Holskov, Mads Boritz Gron, Nana Bule Sejbak, Ole Jakob Muller, Steen Riisgard and Stig Strobaek. View ownership details →
Yes, Novo Nordisk Latvia SIA is registered as an active VAT payer with VAT number LV40203480485.
In 2024, the average gross salary at Novo Nordisk Latvia SIA was approximately 5123,58 € per month (net ~ 3546,32 €). This is an approximate calculation. View salary details →
Novo Nordisk Latvia SIA was founded on April 28, 2023. The company has been operating for 3 years.
| Indicator | Value | Rank | Comparison | |
|---|---|---|---|---|
Company age | 3 years | 257 - 261 | 4% | |
Net revenue | 19 816 379,00 € | 16 - 20 | 93% | |
Profit | 773 715,00 € | 31 - 35 | 88% | |
Equity | 1 096 724,00 € | 53 - 57 | 74% | |
Assets | 6 365 378,00 € | 30 - 34 | 87% | |
Liquidity | 1.23 | - | 40% | |
Profitability | 3.9% | - | 10% | |
Registered capital | 200 000,00 € | - | 90% |
Annual financial report for 2024.
Annual financial report for 2023.
Registered in the Latvian company register.
| Name, surname | Shares | Ownership rights |
|---|---|---|
| Novo Nordisk Region Europe A/S | 200 | 100.00% |
| Name, surname | Nationality | Birth date | |
|---|---|---|---|
| Anders Kaae | DK | - | |
| Barbara Casadei | IT | - | |
| Christopher Ashby Voigt | US | - | |
| Lars Green | DK | - | |
| Lars Henrik Munch | DK | - | |
| Lars Rebien Sorensen | DK | - | |
| Lena Bech Holskov | DK | - | |
| Mads Boritz Gron | DK | - | |
| Nana Bule Sejbak | DK | - | |
| Ole Jakob Muller | DK | - | |
| Steen Riisgard | DK | - | |
| Stig Strobaek | DK | - |